Tigecycline: A glycylcycline antimicrobial agent
References (101)
- et al.
Emerging carbapenemases in gram-negative aerobes
Clin Microbiol Infect
(2002) The emergence and implications of metallo-betalactamases in gram-negative bacteria
Clin Microbiol Infect
(2005)- et al.
Tigecycline: An investigational glycylcycline antimicrobial with activityagainst resistant gram-positive organisms
Clin Ther
(2005) New developments in tetracycline antibiotics: Glycylcyclines and tetracycline efflux pump inhibitors
Drug Resist Updat
(2002)Glycylcyclines: Third-generation tetracycline antibiotics
Curr Opin Pharmacol
(2001)- et al.
In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections
Diagn Microbiol Infect Dis
(2004) - et al.
In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST program, 2004)
Diagn Microbiol Infect Dis
(2005) - et al.
Antimicrobial activity oftigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit
Diagn Microbiol Infect Dis
(2005) - et al.
Tigecycline activity tested against 26,474 bloodstream infection isolates: A collection from 6 continents
Diagn Microbiol Infect Dis
(2005) - et al.
Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004)
Diagn Microbiol Infect Dis
(2005)
Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and noso comial pneumonia
Diagn Microbiol Infect Dis
(2005)
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1203 recent clinical bacterial isolates
Diagn Microbiol Infect Dis
(2000)
Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates
Diagn Microbiol Infect Dis
(2005)
Antimicrobial activity of tigecycline (GAR936) tested against 3498 recent iso lates of Staphylococcus aureus recovered from nosocomial and community-acquired infections
Int J Antimicrob Agents
(2004)
GAR-936 (9-t-butylglycylamidominocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: Preliminary guidelines and interpretive criteria
Int J Antimicrob Agents
(2001)
In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis
Int J Antimicrob Agents
(2000)
Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients
Clin Ther
(2004)
Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline
Int J Antimicrob Agents
(2005)
In vitro activity of GAR-936 against vancomycin-resistant entero cocci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae
Diagn Microbiol Infect Dis
(2000)
Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent
Diagn Microbiol Infect Dis.
(2005)
Efficacy and safety of tigecy cline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial
Int J Infect Dis
(2005)
Tigecycline: Clinical evidence and formulary positioning
Int J Antimicrob Agents
(2005)
Antimicrobial resistance trends and outbreak frequency in United States hospitals
Clin Infect Dis
(2004)
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
J Antimicrob Chemother
(1997)
Staphylococcus aureus resistant to vancomycin—United States, 2002
MMWR Morb Mortal Wkly Rep
(2002)
Public health dispatch: Vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002
MMWR Morb Mortal Wkly Rep
(2002)
Community-associated methicillin-resistant Staphylococcus aureus
Clin Infect Dis
(2005)
Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and recommendations for detection
Antimicrob Agents Chemother
(2005)
First nosocomial outbreak of Pseudomonas aeruginosa producing an integronborne metallo-beta-lactamase (VIM-2) in the United States
Antimicrob Agents Chemother
(2005)
Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates… A Public Health Crisis Brews
Tigecycline: A review of a new glycylcycline antibiotic
J Dermatolog Treat
(2005)
Tigecycline
J Antimicrob Chemother.
(2005)
The glycylcyclines: A comparative review with the tetracyclines
Drugs
(2004)
Tigecycline: A novel glycylcyline
Drugs
(2005)
Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-medicated ribosomal protection
Antimicrob Agents Chemother
(1996)
In vitro activities of tigecycline against the Bacteroides fragilis group
Antimicrob Agents Chemother
(2004)
Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens
Antimicrob Agents Chemother
(2000)
In vitro activity of tigecycline against isolates from pa tients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections
Clin Infect Dis
(2005)
Methicillin-resistant Staphylococcus aureus (1030) collected from a recent global population: Tigecycline in vitro evaluation
Vancomycin-resistant enterococci (VRE): A global problem: Evaluation of tigecycline against recent isolates from multi-centers globally
Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline
Diagn Microbiol Infect Dis
(2004)
Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania
Antimicrob Agents Chemother
(2004)
Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center
J Antimicrob Chemother
(2003)
Determining tigecycline's in vitro activity against multi-drug re sistant Enterobacteriaceae from the TEST program—global data
Activity of tigecycline tested against tetracycline-resistant Enterobacteriaceae
In vitro activity of tigecycline and comparative antimicrobial agents against ampicillin-resistant Haemophilus influenzae isolates
Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution and MIC Interpretive Breakpoints: Informational Supplement—Second Edition
(2006)
Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method
Antimicrob Agents Chemother
(2005)
Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines
J Antimicrob Chemother
(2005)
Cited by (144)
Biodegradable polymeric scaffolds and hydrogels in the treatment of chronic and infectious wound healing
2023, European Polymer JournalLinezolid shows high safety and efficacy in the treatment of Pythium insidiosum keratitis in a rabbit model
2021, Experimental Eye ResearchTigecycline therapy in pediatric patients with multidrug resistant bacteremia
2020, Enfermedades Infecciosas y Microbiologia ClinicaSystemic Antibacterial Agents
2020, Comprehensive Dermatologic Drug Therapy, Fourth Edition
Copyright © 2006 Excerpta Medica, Inc. Published by Elsevier Inc. All rights reserved.